Danaher Corp. (DHR)

97.54
0.07 0.07
NYSE : Health Technology
Prev Close 97.47
Open 97.50
Day Low/High 96.82 / 98.42
52 Wk Low/High 78.97 / 104.82
Volume 1.89M
Avg Volume 2.38M
Exchange NYSE
Shares Outstanding 696.60M
Market Cap 66.46B
EPS 3.60
P/E Ratio 24.19
Div & Yield 0.56 (0.58%)

Latest News

Weekly Roundup

Markets extend losses in volatile week.

Adding More Honeywell

Honeywell fits what we are looking to buy in this market -- quality names that reported strong quarters and are now trading at a discount.

Weekly Roundup

Big market selloff

Bullish Danaher Stock Has Higher Aspirations

Bullish Danaher Stock Has Higher Aspirations

Buy strength in DHR shares.

Cramer: I See Stocks That Are Overdone to the Downside

Cramer: I See Stocks That Are Overdone to the Downside

Maybe better hunting tomorrow.

Jim's Daily Rundown

Jim discusses our trades from this morning, earnings from Danaher and Nucor, and the JPMorgan-Berkshire Hathaway-Amazon healthcare deal.

Danaher Beats Estimates on Expanded Gross Margins

Quarterly numbers driven by growth in life sciences and diagnostics businesses.

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

You might actually be grateful that stocks took one on the jaw on Monday.

Dow Selloff, Thomson Reuters, Jamie Dimon, Exxon, Waymo - 5 Things You Must Know

Dow Selloff, Thomson Reuters, Jamie Dimon, Exxon, Waymo - 5 Things You Must Know

The Dow is looking at its second consecutive triple-digit decline on Tuesday, Thomson Reuters confirms it's in talks to sell a stake in its financial and risk business, and Jamie Dimon says he'll stay at JPMorgan Chase for five more years.

Weekly Roundup

Markets extend rally.

Jim's Daily Rundown

Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.

A Closer Look at GE Ahead of Earnings Wednesday

Could Danaher be interested in GE's Life Sciences business?

Jim's Daily Rundown

Jim discusses our outlook on Allergan, JPMorgan's investment plan, Microsoft, Constellation Brands, and more!

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

Weekly Roundup

Broader markets close higher as earnings season picks up.

Jim's Daily Rundown

Jim recaps Schlumberger's latest financial results and more.

Jim's Daily Rundown

Jim discusses yesterday's market reversal and what to look for, GE news, Apple, healthcare and the financials.

Jim's Daily Rundown

Jim discusses GE, Citigroup's earnings, Facebook's update to its news feed update, and our price target for Activision.

Weekly Roundup

Markets extend their start of the year rally

China Price Index Data Supports Global Expansion View

The latest consumer and producer price indexes are good news for Apple and other portfolio names with large exposure to China.

Jim's Daily Rundown

In today's video, Jim discusses our newest initiation in Constellation Brands, Danaher at the JP Morgan Healthcare conference, and energy stocks.

Danaher Simply Blew It Away at This Big Healthcare Conference Tuesday

Danaher Simply Blew It Away at This Big Healthcare Conference Tuesday

The CEO of the diversified machinery company says its core growth as well as earnings per share will top its guidance range when it releases the numbers at the end of the month.

Cramer: Lessons From the Market and ICR

Cramer: Lessons From the Market and ICR

You can make a case to buy any of the stocks of the companies at ICR.

Allergan CEO Saunders Increases the Transparency of the Future

Investors are regaining interest in the stock due to the positive risk/reward.

Weekly Roundup

Markets roared to begin the new year.

TheStreet Quant Rating: A- (Buy)